Therapeutically, the blockade of IL-17A using monoclonal antibodies (such as secukinumab and ixekizumab) has demonstrated efficacy in diseases like psoriasis and ankylosing spondylitis (8), suggesting its potential applicability in neurological disorders mediated by neuroinflammation. This evidence concerns the gene IL17A and nervous system disorder.